The US FDA approves Bayer's Sunharbo (asundexian), a Factor XIa inhibitor, to prevent recurrent strokes and high-risk mini-strokes. BayerBlood Thinnersstroke preventionThe once-daily Factor XIa inhibitor is approved for patients with a previous non-cardioembolic stroke or a high-risk transient ischemic attack, marking a new approach to preventing blood clots. Editorial Note: This content has been prepared using information from official announcements, regulatory communications, scientific publications, conference presentations, or other verified sources.